Haoqiang Ying

List of Publications by Year
in descending order

67 papers	13,868 citations	71102 41 h-index	98798 67 g-index
71 all docs	71 docs citations	71 times ranked	21988 citing authors

#	Article	IF	Citations
1	Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARÎ´. Nature Communications, 2022, 13, 2665.	12.8	25
2	Targeting syndecan-1: new opportunities in cancer therapy. American Journal of Physiology - Cell Physiology, 2022, 323, C29-C45.	4.6	11
3	Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling. Cancer Research, 2021, 81, 1528-1539.	0.9	5
4	Decoding the role of long noncoding RNAs in the healthy aging of centenarians. Briefings in Bioinformatics, 2021, 22, .	6.5	12
5	Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Cancer Research, 2021, 81, 4054-4065.	0.9	24
6	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nature Communications, 2021, 12, 4626.	12.8	31
7	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science, 2021, 373, eabj0486.	12.6	99
8	KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. Cancer Letters, 2021, 517, 66-77.	7.2	22
9	Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. Oncogene, 2021, 40, 6759-6771.	5.9	13
10	Hyaluronic acid fuels pancreatic cancer cell growth. ELife, 2021, 10, .	6.0	45
11	Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nature Communications, 2021, 12, 7041.	12.8	43
12	Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer. Oncogene, 2020, 39, 1152-1164.	5.9	12
13	A chiralityâ€dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics. International Journal of Cancer, 2020, 146, 2822-2828.	5.1	9
14	Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Reports, 2020, 33, 108293.	6.4	39
15	Recent insights into the biology of pancreatic cancer. EBioMedicine, 2020, 53, 102655.	6.1	78
16	Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Cancer Discovery, 2020, 10, 608-625.	9.4	119
17	The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer. American Journal of Cancer Research, 2020, 10, 2621-2634.	1.4	8
18	<scp>ATRX</scp> loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization. EMBO Journal, 2019, 38, e96659.	7.8	71

#	Article	IF	Citations
19	Glucose Metabolism in Pancreatic Cancer. Cancers, 2019, 11, 1460.	3.7	74
20	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine, 2019, 25, 628-640.	30.7	476
21	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature, 2019, 568, 410-414.	27.8	129
22	Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight, 2019, 4, .	5.0	102
23	YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. JCI Insight, 2019, 4, .	5.0	46
24	Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell, 2018, 33, 752-769.e8.	16.8	58
25	Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. Journal of Clinical Investigation, 2018, 128, 1283-1299.	8.2	163
26	Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nature Communications, 2018, 9, 4945.	12.8	170
27	Expression of Long Noncoding RNA <i>YIYA</i> Promotes Glycolysis in Breast Cancer. Cancer Research, 2018, 78, 4524-4532.	0.9	59
28	Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature, 2017, 542, 119-123.	27.8	209
29	Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nature Communications, 2017, 8, 14437.	12.8	77
30	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature, 2017, 542, 362-366.	27.8	105
31	KRAS-related proteins in pancreatic cancer. , 2016, 168, 29-42.		151
32	Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature, 2016, 536, 479-483.	27.8	843
33	Functional annotation of rare gene aberration drivers of pancreatic cancer. Nature Communications, 2016, 7, 10500.	12.8	58
34	Genetics and biology of pancreatic ductal adenocarcinoma. Genes and Development, 2016, 30, 355-385.	5.9	416
35	Inhibition of Cdc42 is essential for Mig-6 suppression of cell migration induced by EGF. Oncotarget, 2016, 7, 49180-49193.	1.8	12
36	Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms. Cancer Research, 2015, 75, 2109-2119.	0.9	33

#	Article	IF	Citations
37	Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. Cancer Research, 2015, 75, 1091-1101.	0.9	68
38	Neuroplastic Changes Occur Early in the Development of Pancreatic Ductal Adenocarcinoma. Cancer Research, 2014, 74, 1718-1727.	0.9	140
39	Cancer signaling: when phosphorylation meets methylation. Cell Research, 2014, 24, 1282-1283.	12.0	9
40	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature, 2014, 514, 628-632.	27.8	998
41	Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. Cell, 2014, 158, 185-197.	28.9	553
42	FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells. EMBO Journal, 2013, 32, 2589-2602.	7.8	130
43	Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature, 2013, 496, 101-105.	27.8	1,562
44	ZNF365 Promotes Stability of Fragile Sites and Telomeres. Cancer Discovery, 2013, 3, 798-811.	9.4	15
45	Rapamycin Inhibits IGF-1-Mediated Up-Regulation of MDM2 and Sensitizes Cancer Cells to Chemotherapy. PLoS ONE, 2013, 8, e63179.	2.5	14
46	microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-Î² Signaling in Glioblastoma. Cancer Discovery, 2012, 2, 736-749.	9.4	99
47	STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes and Development, 2012, 26, 1459-1472.	5.9	101
48	Antitelomerase Therapy Provokes ALT and Mitochondrial Adaptive Mechanisms in Cancer. Cell, 2012, 148, 651-663.	28.9	240
49	Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism. Cell, 2012, 149, 656-670.	28.9	1,587
50	Pancreatic cancers require autophagy for tumor growth. Genes and Development, 2011, 25, 717-729.	5.9	1,224
51	PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-ÎºBâ€“Cytokine Network. Cancer Discovery, 2011, 1, 158-169.	9.4	186
52	PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and Gliomas. Cancer Cell, 2010, 17, 497-509.	16.8	224
53	Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6912-6917.	7.1	109
54	Inhibition of RelB by 1,25â€dihydroxyvitamin D₃ promotes sensitivity of breast cancer cells to radiation. Journal of Cellular Physiology, 2009, 220, 593-599.	4.1	43

#	Article	IF	Citations
55	FoxOs Cooperatively Regulate Diverse Pathways Governing Neural Stem Cell Homeostasis. Cell Stem Cell, 2009, 5, 540-553.	11.1	418
56	p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature, 2008, 455, 1129-1133.	27.8	658
57	Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19372-19377.	7.1	134
58	Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies. Science, 2007, 318, 287-290.	12.6	849
59	Targeting Retinoblastoma Protein for Degradation by Proteasomes. Cell Cycle, 2006, 5, 506-508.	2.6	58
60	Increased expression of MDM2, cyclin D1, and p27Kip1 in carcinogen-induced rat mammary tumors. Journal of Cellular Biochemistry, 2005, 95, 875-884.	2.6	21
61	DNA-Binding and Transactivation Activities Are Essential for TAp63 Protein Degradation. Molecular and Cellular Biology, 2005, 25, 6154-6164.	2.3	42
62	Oncogenic Signaling Pathways Activated in DMBA-Induced Mouse Mammary Tumors. Toxicologic Pathology, 2005, 33, 726-737.	1.8	143
63	MDM2 Promotes Proteasome-Dependent Ubiquitin-Independent Degradation of Retinoblastoma Protein. Molecular Cell, 2005, 20, 699-708.	9.7	239
64	The Central Acidic Domain of MDM2 Is Critical in Inhibition of Retinoblastoma-mediated Suppression of E2F and Cell Growth. Journal of Biological Chemistry, 2004, 279, 53317-53322.	3.4	69
65	The MDM2 RING finger is required for cell cycle-dependent regulation of its protein expression. FEBS Letters, 2003, 544, 218-222.	2.8	17
66	Deregulation of Cdc2 kinase induces caspase-3 activation and apoptosis. Biochemical and Biophysical Research Communications, 2003, 302, 384-391.	2.1	15
67	Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. ELife, 0, 11, .	6.0	32